TY - JOUR
T1 - Diagnosis and management of AML in pediatric patients
T2 - consensus recommendations from an international expert panel
AU - Zwaan, C. Michel
AU - Tasian, Sarah K.
AU - Aplenc, Richard
AU - Brodersen, Lisa E.
AU - Buldini, Barbara
AU - De Moerloose, Barbara
AU - Dworzak, Michael N.
AU - Fogelstrand, Linda
AU - Gibson, Brenda E.S.
AU - Goemans, Bianca F.
AU - Hasle, Henrik
AU - Hirsch, Betsy A.
AU - Kaspers, Gertjan J.L.
AU - Klusmann, Jan Henning
AU - Kutny, Matthew A.
AU - Lehrnbecher, Thomas
AU - Locatelli, Franco
AU - Meshinchi, Soheil
AU - Petit, Arnaud
AU - Pigazzi, Martina
AU - Tierens, Anne
AU - Kolb, E. Anders
AU - Reinhardt, Dirk
AU - Tomizawa, Daisuke
AU - Cooper, Todd M.
N1 - © 2026 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2026/4/2
Y1 - 2026/4/2
N2 - The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
AB - The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
KW - Young Adult
KW - Humans
KW - Adolescent
KW - Leukemia, Myeloid, Acute/diagnosis
KW - Disease Management
KW - Child
KW - Consensus
KW - Practice Guidelines as Topic
UR - https://www.scopus.com/pages/publications/105034570913
U2 - 10.1182/blood.2024027904
DO - 10.1182/blood.2024027904
M3 - Comment/debate
C2 - 41105890
AN - SCOPUS:105034570913
SN - 0006-4971
VL - 147
SP - 1532
EP - 1561
JO - Blood
JF - Blood
IS - 14
ER -